ADPKD Guide
Readable, evidence-first ADPKD treatment, symptoms, diet, trials, and research updates for patients, families, and clinicians.
Last sweep: Jun 1, 2026
What’s New Methodology References Support GitHub
Patient Guide Treatment Trials Cure
More
What’s New Newly Diagnosed Tolvaptan Diet Symptoms Clinicians Methodology References Support
ADPKD Patient Guide Patient reading mode

ADPKD treatment, diet, symptoms, and lifestyle guide

What helps now, what is promising, and what is still weak evidence.

Last reviewed: June 1, 2026

Proven, promising, and not proven

Color-coded so you can see at a glance how strong the evidence is for each.

Proven / best-supported Proven

  • Tolvaptan in appropriate high-risk adults Proven
  • Risk-stratified intervention timing (imaging + eGFR trajectory) Proven
  • Tight blood pressure management Proven

Promising Promising

  • SGLT2 inhibitors in ADPKD Promising
  • SGLT2 inhibitors in ADPKD Promising
  • Metabolic and ketogenic strategies Promising

Not proven Not proven

  • Any claimed human cure Not proven
  • High water intake as a standalone disease-modifying prescription Not proven
  • Early gene-editing headlines as current therapy Not proven

Recent movement

  • Key new evidence this run , GLPG2737 / CFTR inhibition failed in the phase 2a MANGROVE study: it did not reduce htTKV growth or slow eGFR decline versus placebo in rapidly progressive ADPKD (PMID42201338).
  • Four-track review outcome
  • What strengthened , The negative CFTR result cleaned up a weak hypothesis.